Inactive Instrument

Genomic Vision

Equities

GV

FR0011799907

Biotechnology & Medical Research

Genomic Vision : First half 2018 results

July 25, 2018 at 05:39 am EDT

undefined

Attachments

Original document
Permalink

Disclaimer

Genomic Vision SA published this content on 25 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 July 2018 09:38:03 UTC

Latest news about Genomic Vision

Genomic Vision Announces Revenue Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Genomic Vision: suspension of payments, recovery in sight	Nov. 06	CF
Genomic Vision Files for Receivership at French Court	Nov. 06	MT
Genomic Vision: RCA service offering to be expanded	Nov. 02	CF
Genomic Vision Expands Its Replication Combing Assay Service Offering	Nov. 02	CI
Genomic Vision: Winance no longer holds any shares	23-10-18	CF
Genomic Vision Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Genomic Vision Launches HexaCard	23-07-18	CI
Genomic Vision: Ayoub Kriem exceeds 5% of capital and voting rights	23-06-26	CF
Genomic Vision Société Anonyme announced that it has received ?6 million in funding from Winance Investment, LLC	23-06-22	CI
Genomic Vision: distribution agreement with CliniSciences	23-06-22	CF
Genomic Vision: technology agreement with ICR London	23-06-20	CF
Genomic Vision: share price rises, financial visibility welcomed	23-05-05	CF
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony...	23-04-21
Genomic Vision Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Genomic Vision Joins France Biolead to Advance Innovation and Production of Biopharmaceuticals in France	23-04-03	CI
Global markets live: Blackberry, Meta Platforms, Rivian, GM...	23-03-07
Genomic Vision launches FiberSmart® technology	23-03-07	CF
Genomic Vision Launches FiberSmart, AI-Powered Software for Automating Genomic Analysis	23-03-07	CI
Genomic Vision Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-28	CI
Genomic Vision's DNA Characterization Technology Evaluated Successfully in US	23-02-21	MT
The US National Institute of Standards and Technology Evaluates the Use of Genomic Vision Applications for Genetic Variant Characterization	23-02-21	CI
Global markets live: Airbus, Tesla, Meta, Commerzbank...	23-02-20
Genomic Vision: issue of a tranche of OCABSA bonds	23-02-20	CF
Genomic Vision appoints Director of Operations	23-01-24	CF

Chart Genomic Vision

Duration

Period

More charts

Company Profile

Genomic Vision specializes in developing genetic diseases diagnosis tests and cancer genomic analysis. The group uses molecular combing technology which allows direct visualization of DNA individual molecules in order to detect the quantitative and qualitative changes of the genome and determine their role in targeted pathology. The activity is organized around 3 sources of income: - sales of equipment and consumables: to academic laboratory centers using the molecular combing technology for research purposes; - license and royalties income: income from collaboration with Quest Diagnostics; - sales of software, testing kits and related consumables.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research